ID exam 1 Flashcards
xWhat is the goal of PK
increase effectiveness of treatment and/or decrease the side effects of the treatment
____ is used to develop a model for designing individual drug regimens
PK
What is PD
describe characteristics of interaction between substance, active site, and action (think antimicrobial affect on pathogen)
What are the 2 categories that antimicrobial agents are classified as exhibiting
concentration dependent activity
non concentration dependent activity
What is concentration dependent activity of antimicrobial agents
rate/extent of bactericidal activity increases with increasing antimicrobial concentrations
goal to optimize peak: MIC (AUC:MIC)
What is non-concentration dependent activity of antimicrobial agents
rate/extent of killin do not increase with increasing antimicrobial concentration; instead it is increased by length of exposure
goal to optimize time concentrations remain above MIC (t>MIC)
What is the blood culture pathway
collection: sample incubated
alert: machine alerts for positive culture
gram stain: tech performs STAT stain
incubation: culture plates
What is the timeline for antimicrobial therapy
clinical illness
empiric antibiotics
culture processing
ID
targeted antibiotics
What is the time frame for gram stain, blood culture, EMR view
gram stain: 24-48 h
blood culture: additional 24-48 h
EMR view: additional 24 h
What are all the components of targeted antibiotics regimen
pathogen
indication/site of infection
dose
route
duration
What is MIC (minimum inhibitory concentration)
Lowest antimicrobial concentration that inhibits visible bacterial growth
What is MBC (minimum bactericidal concentration)
lowest antimicrobial concentration that results in microbial death
Broth microdilution susceptibility testing
inoculation with various antimicrobial concentrations (standard for testing)
What drugs focus on the T>MIC (time dependent killing) PD curve
beta lactams
tetracycline
oxazolidinones
What drugs focus on the AUC/MIC PD curve
fluoroquinolones
macrolides
ketolides
glycopeptides
What is the goal of beta lactams
keep serum concentrations above MIC for at least 40-70% of dosing interval
(max kill at 4-5x MIC, focus on T>MIC)
What is the Vd, half-life, and protein binding of beta lactams, excretion
Vd: 0.15-0.3 L/kg
half-life: 1-2 hr
protein binding: 25% or less
excretion via glomerular filtration and tubular secretion
Critically ill patients may have changed PK derangement what are these principles they effect
change in Vd
large volume of fluid resuscitation
vasopressor use
hypoalbuminemia
augmented renal clearance
Pharmacy to dose (PTD) - vancomycin PK/PD
formal pharmacy consult for pharmacist managed dosing and policy directed management
Therapeutic Drug Monitoring (TDM) - vancomycin PK/PD
assay procedures to determine drug concentrations in plasma, further interpreted and applied to develop safe and effective regimens
What is the difference between C1 and C2 - vancomycin PK/PD
C1 peak (1-2 hr after end of infusion)
C2 trough (end interval concentration)
What is AUC/MIC
integrated quantity of cumulative drug exposure for a defined period of time
average serum drug concentration during time period
what is the goal AUC of vancomycin
target: 500 mcgh/mL
range: 400-600 mcgh/mL
(500-600 for MRSA, endocarditis, menigitis)
Vancomycin MIC <1 and MIC >2 meaning
MIC >1 = 100% change of achieving goal AUC/MIC >400
MIC >2 mcg/mL - goal not achievable in patient with normal renal function
What is the trough level for vancomycin
15-20 mcg/mL
Vancomycin nephrotoxicity levels
AUC/MIC >400
trough <15 mcg/mL
Why is AUC in vancomycin a high variability
depends on dose and renal function
trough concentration explains 40% of inter0individual variability in AUC
For vancomycin what should the loading dose be in patients with severe infections
20-25 mg/kg
When to get trough level for vancomycin
30 min -1 hr prior to next dose
must be at least 6 hours after peak level
What is the semi-synthetic aminoglycoside
amikacin
(genta and tobra natural)
Aminoglycosides consists of _____ sugars joined by _______ bonds to an aminocyclitol nucleus
amino
glycosidic
MOA of aminoglycosides (gram negative only)
-inhibit protein synthesis by binding to 16S ribosomal rRNA of 30s ribosome (irreversible bond lead to PAE)
-cause cell damage by mistranslation and incorrect formation of polypeptides
Synergy in aminoglycosides
synergy: use with cell-wall active antibiotic to increase aminoglycoside uptake despite small doses
Amikacin is resistant to enzyme ____________
inactivation (remains stable against organisms resistant to genta/tobra)
Aminoglycoside ADME
a: polar
d: Vd 0.3 L/kg
m: n/a
e: urine, t1/2: 1-4 hr
Aminoglycosides are ______________ dependent drugs
concentration (higher peak = better effects) MIC 10:1
What is the aminoglycoside dose for hartford? urban-craig nomogram?
hartford: 7 mg/kg
urban-craig: 5 mg/kg
level drawn 8-12 hr after start of infusion
What are the common examples of antimicrobial resistance
MRSA
CRE (carbapenem-resistant enterococcus)
VRE (vancomycin-resistant enterococcus)
ESBLs (extended spectrum beta lactamases)
What is an efflux pump
antimicrobial actively pumped out of cell
What is entry inhibition
antimicrobial actively blocked from entering cell
Antimicrobial Resistance inactivation and target site modifcation
inactivation: breakdown of active drug
modification: active drug unable to elicit effect
What are gram negative pathogens commonly caused by
intra-abdominal infection (IAIs), urinary tract infections, ventilator-associated pneumonia (VAP), bacteremia
Beta-lactamases mechanism of resistance
cleave beta lactam ring to inactivate
ESBL are plasmid encoded
there are different types that are dependent on inactivation/hydrolysis
What is horizontal transfer of resistance
transfer of resistance genes from one organism to another
-transduction (bacteriophage/integron)
-conjugation (plasmid)
-transformation (chromosomal DNA/plasmid)
ESBLs may have the framework to hydrolyze/inactive all agents with ester/amide bond but what
this is not always the case
Efflux pumps/permeability
pumps are proteins w/in membrane that export antibiotics from intracellular matrix
outer membrane porins may decrease entry of antibiotic into cell
Target site modification: fluoroquinolone resistance and aminoglycoside resistance
fluoroquinolone resistance: target site protection/modification to alter agent binding
aminoglycoside resistance: alteration of ribosomal proteins that lead to high level resistance
Gram positive pathogens common cause
skin and structure infections, bacteremia, hospital/community acquired pneumonia
Staphylococci: plasmid-encoded beta lactamase nafcillin/cefazolin generally stable
inactivation
Staphylococci: PBP2a has low affinity for beta lactams (show MRSA)
target replacement
Staphylococci: leads to linezolid resistance often with other concomitant mutation
target modification
Staphylococci: repulusion of antibiotic due to increase in cell envelope charge
drug entry
Enterococci: rare-usually found in E. faecalis
inactivation
Enterococci: usually acquired resistance may differ depending on enterococcus spp
target replacement
Enterococci: reason why cephalosporins do not cover enterococcus spp
target modification
Enterococci: repulsion of antibiotic due to increase in cell envelope charge
drug entry
Streptococci: type of PBP will determine which beta lactam resistance pattern you will see
target modification
BioFire and rapid diagnostic gram negative bacteria
E coli
Pseudomonas aeruginosa
BioFire and rapid diagnostic gram positive bacteria
enterococcis faecalis
s. aureus
BioFire and rapid diagnostic yeast
candida albicans
candida glabrata
BioFire and rapid diagnostic antimicrobial resistance genes
methicillin resistance
-mecA/C
-MRSA
In a prospective audit and feedback you reports on the financial impact of interventions and feedback based on what 3 things
dose adjustments
alternative agents
cost of therapy
ID pharmacy in policy change
small steps
always identify key stakeholders
implement education and process change
takes time
Penicillin MOA
inhibit bacterial cell wall synthesis by binding to penicillin binding proteins
(half liver 1 hour, gets in CNS)
Time dependent killing of penicillins
Time > MIC
goal to keep serum concentration above MIC for at LEAST 50-60% OF DOSING INTERVAL)
Allergy for penicillin
range in severity
all penicillins may cause neutropenia, neurotoxicity, or renal injury (mainly nadcillin/oxacillin)
Cephalosporins MOA
inhibition of bacterial cell wall synthesis by binding to penicillin binding proteins
(half life 1-2 hr, CNS penetration)
Time dependent killing for cephalosporins
time > MIC
goal to keep serum concentration above MIC for at least 60-70% of dosing interval
Cephalosporins allergy
range in severity
less frequent than penicillins
low rate of cross reactivity especially with higher generations of 2-4
Cephalosporins adverse effects
GI
variable association with CDI
neutropenia, neurotoxicity, renal injury
local reactions are common
Carbapenems MOA
inhibition of bacterial cell wall synthesis by binding to penicillin binding proteins
(half life 1-2 hr, CNS penetration)
Carbapenems time dependent killing
time > MIC
goal to keep serum concentration above MIC for at least 40-50% of dosing interval
Carbapenems allergy
low incidence of allergy
minimal cross reactivity
neurotoxicity caution with seizure disorders in general anti epileptic drug drug interactions
Aminoglycosides MOA
inhibition of protein synthesis by binding to 30S subunit, leading to misreading in translation process (rapid bactericidal)
1-4 hr half life
What adverse effect of aminoglycosides can not be reversed
ototoxicity
(nephrotoxicity can happen and can be reversed)
Aminoglycoside concentration dependent killing
peak: MIX/AUC:MIC
goal to maximuze peak/min trough
Fluoroquinolones MOA
inhibition of bacterial topoisomerases leading to inhibition of DNA replication and transcription
(4-12 hr half life)
Topoisomerase II is gram ________ while Topoisomerase 4 is gram __________
negative
positive
Fluoroquinolones concentration dependent killing
AUC:MIC
goal to maximize AUC:MIC ratio based on organism (higher doses for gram negative organisms)
Fluoroquinolones adverse effects
GI
CNS
QT prolongation
hypo/hyperglycemia
tendonitis
increase aortic dissection
increase lft
interaction with cation
Macrolide MOA
inhibition of RNA dependent protein synthesis bind to 50S ribosomal subunit to prevent bacterial growth
(68-72 hr half life)
concentration dependent killing
Macrolide adverse effect
GI
LFT increase
potential headache
CYP3A4 inhibitors (drug-drug interactions with statin, warfarin, azithromycin inhibition weaker)
Lincosamide MOA
bind to 50S ribosomal subunit to prevent protein synthesis
half-life 3 hours
concentration dependent killing
Lincosamide adverse effects
GI
metallic tase
rash
Tetracycline MOA
bind to 30S ribosomal subunit to prevent protein synthesis
half life 12-24 h
concentration dependent killing
90-100 PO absorption
Tetracycline adverse effects
NVD
esophagitis
photosensitivity
rash
hepatotoxicity (rare)
deposition into teeth
TMP-SMX MOA
TMP: bind to dihydrofolate reductase to inhibit formation of folic acid
SMX: inhibit synthesis of dihydrofolic caid
Inhibit DNA synthesis
10 hr half life
90-100% PO absorption
time dependent killing
TMP-SMX adverse effects
rash, itching
bone marroe suppression
crystalluria of SMX component in renal tubules
hyperkalemia
caution with DDI: warfarin, anticonvulsants, ACE/ARB
Vancomycin MOA
form complex with d-ala-d-ala portion of peptide to prevent peptidoglycan syntheses
AUC: MIC PK
Vancomycin ADR
infusion related reaction
nephrotoxicity
ototoxity (rare)
Daptomycin MOA
bind to calcium and insertion into cell membrane causing rapid depolarization and cell lysis
8-10 hr half-life
urine secretion
AUC: MIC/ Peak: MIC
Daptomycin ADR
myopathies
CK elevation
injection site reaction
Linezolid MOA
inhibition of bacterial protein sysnthesis bind to 23S rRNA or 50S subunit to prevent translation complex
half life 5 hr
gets into CNS
Linezolid adverse effect
GI
myelosuppression
peripheral neuropathies
serotonin syndroms
Metronidazole MOA
intracellular reduction to produce reactive metabolites; damage DNA
half-life 8-10 hr
Metronidazole ADR
peripheral neuropathy
metallic taste
disulfiram reaction
Amphotericin B killing curve
concentration dependent killing
Amphotericin B Infusion Reaction
fever, chills, rigors, N/V, muscle pain
pre-medicate with NSAID, APAP 30-60 min before
(hypotension, bronchospasm, arrhythmia, anaphylaxis)
Liposomal amphotericin infusion reactions
Triad
-chest pain, dyspnea, hypoxia
-flank pain, ab pain, leg pain
-flushing, urticaria
Occurs within 5 minutes
-stop infusion
-give diphenhydramine
-slow infusion when re-challenged
Amphotericin B nephrotoxicity
tubular dysfunction and vasoconstriction of afferent arteriole
dose limiting toxicity
risk factors:
nephrotoxins, daily dose, cumulative dose, CKD
Amphotericin B nephrotoxicity prevention
saline loading with 500-1000 ml 0.9% NaCl before and after administering
adequate hydration
electrolyte correction
using lipid formulation when possible
Amphotericin B nephrotoxicity occurrence
Ambisome < Abelcet < Conventional